Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dianthus TherapeuticsDNTH +1.43%22 Cash-to-Debt is 689.05 as of Jun. 2026, which is 126% above its 10-year median of 305.14. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $3.92 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,371 Biotechnology companies, Dianthus Therapeutics ranks better than 84.9% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dianthus Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 689.05.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Dianthus Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Dianthus Therapeutics's Cash-to-Debt or its related term are showing as below:
DNTH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 95.8 Med: 305.14 Max: No Debt
Current: 689.05
During the past 5 years, Dianthus Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 95.80. And the median was 305.14.
DNTH's Cash-to-Debt is ranked better than 84.9% of 1371
companies
in the Biotechnology industry
Industry Median: 6.78
vs DNTH: 689.05
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Dianthus Therapeutics Cash-to-Debt Related Terms
Dianthus Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Dianthus Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Dianthus Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics (DNTH) has a Cash-to-Debt of 689.05 as of Jun. 2026. This is 126% above median its historical median of 305.14. Over the past decade, Dianthus Therapeutics' Cash-to-Debt has ranged from 95.80 to 10,000.00. According to the industry distribution chart, Dianthus Therapeutics ranks #207 out of 1371 companies in the Biotechnology industry, placing it in the top 15.1%.
Is Dianthus Therapeutics' Cash-to-Debt too high?
Dianthus Therapeutics' current Cash-to-Debt of 689.05 is 126% above median its 10-year median of 305.14. Over the past 10 years, this metric has ranged from a low of 95.80 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Dianthus Therapeutics' value of 689.05 is 10063% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #207 out of 1371 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Cash-to-Debt compare to SRRK and DFTX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #207 out of 1371 companies for Cash-to-Debt. This places Dianthus Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.78. Dianthus Therapeutics' value of 689.05 is 10063% above this benchmark. Historically, Dianthus Therapeutics' own Cash-to-Debt has ranged from 95.80 to 10,000.00 over the past decade. While the company's 10-year median is 305.14 vs. the industry median of 6.78, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,371 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current Cash-to-Debt of 689.05 is 10063% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current Cash-to-Debt is 689.05, which is 126% above median its own 10-year median of 305.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.92, compared to a current price of $111.09 — trading 2733.9% above its estimated fair value. The current Cash-to-Debt is 689.05, which is 126% above median its 10-year median of 305.14 and 10063% above the Biotechnology industry median of 6.78. Dianthus Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Cash-to-Debt is 689.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (DNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of $111.09 is trading 2733.9% above its estimated GF Value™ of $3.92.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for DNTH:
Cash-to-Debt: 689.05 (126% above median its 10-year median of 305.14)
GF Value™: $3.92 vs. price of $111.09 (2733.9% above fair value)
Industry Position: 10063% above the Biotechnology median (#207 of 1371)
No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for DNTH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNTH has been successfully added to your 
